CytomX Therapeutics Stock Math Transform Exponential Price Movement
| CTMX Stock | USD 4.87 -0.01 -0.20% |
| Symbol |
Transformation |
The output start index for this execution was zero with a total number of output elements of sixty-one. CytomX Therapeutics Price Movement is a mathematical transformation function to describe exponentially increasing price patterns.
CytomX Therapeutics Technical Analysis Modules
Most technical analysis of CytomX Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for CytomX from various momentum indicators to cycle indicators. When you analyze CytomX charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Stock Overview, Methodology & Data Sources
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California. Cytomx Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 174 people. Market structure and macro sensitivity help explain how CytomX Therapeutics behaves across regimes. Market sensitivity remains generally comparable to wider market conditions. CytomX Therapeutics has a market cap of 826.84 M, ROE of 66.76%.
Methodology
Unless otherwise specified, financial data for CytomX Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. CytomX (USA Stocks:CTMX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for CytomX Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
CytomX Therapeutics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Rifka Kats - Member of Macroaxis Editorial BoardAlign your values with your investing style
Using CytomX Therapeutics inside a theme workflow gives investors a structured way to compare related stocks, funds, ETFs, and crypto assets before allocating capital. The practical benefit is that the selected idea can be tuned either for higher upside or for tighter risk control.
Thematic Opportunities
Explore Investment Opportunities
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Blockchain Invested few shares | |
 | Momentum Invested over 20 shares | |
 | Macroaxis Index Invested over 60 shares | |
 | Adviser Favorites Invested few shares | |
 | Advertising Invested few shares | |
 | Data Storage Invested few shares | |
 | Hedge Favorites Invested over 200 shares | |
 | Driverless Cars Invested few shares | |
More Resources for CytomX Stock Analysis
A comprehensive view of CytomX Therapeutics starts with financial statements and ratio context. Ratio context helps frame profitability, efficiency, and growth trends for CytomX Therapeutics Stock. Selected reports below provide context for CytomX Stock:CytomX Therapeutics has a market cap of 826.84 M, operating margin of -2.64%, ROE of 66.76%. Review Trending Equities for broader portfolio context. This reflects a position in CytomX Therapeutics within the allocation view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. Before investing in CytomX Stock, review our How to Buy CytomX Therapeutics guide for key considerations.Analysis related to CytomX Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Understanding CytomX Therapeutics includes distinguishing between market value and book value, where book value reflects CytomX's accounting equity. CytomX Therapeutics' market capitalization is 826.84 M. With a P/B ratio of 7.7, the market values CytomX Therapeutics well above its book equity. Enterprise value stands at 688.81 M. Intrinsic value reflects what CytomX Therapeutics' fundamentals imply about worth, which may differ from both the trading price and the book figure. Analytical frameworks help reconcile those views.
It is useful to distinguish CytomX Therapeutics' value from its trading price, which are computed with different methods. For CytomX Therapeutics, key inputs include a P/B ratio of 7.7, a profit margin of 24.66%, ROE of 66.76%, and revenue of 138.1 M. The quoted price is simply the exchange level where supply meets demand.